Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by US Bancorp DE

US Bancorp DE decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 72.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130 shares of the company’s stock after selling 5,736 shares during the quarter. US Bancorp DE’s holdings in Protagonist Therapeutics were worth $82,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. raised its stake in Protagonist Therapeutics by 1,729.3% in the 3rd quarter. Victory Capital Management Inc. now owns 130,797 shares of the company’s stock worth $5,886,000 after acquiring an additional 123,647 shares during the last quarter. Mutual of America Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics during the third quarter worth about $399,000. Thrivent Financial for Lutherans purchased a new stake in Protagonist Therapeutics in the third quarter valued at approximately $2,082,000. Quest Partners LLC increased its holdings in Protagonist Therapeutics by 885.1% in the 3rd quarter. Quest Partners LLC now owns 23,947 shares of the company’s stock worth $1,078,000 after buying an additional 21,516 shares during the period. Finally, Segall Bryant & Hamill LLC raised its position in Protagonist Therapeutics by 1.5% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 120,301 shares of the company’s stock worth $5,414,000 after buying an additional 1,739 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $53.01 on Tuesday. The stock has a 50 day simple moving average of $39.93 and a 200-day simple moving average of $42.31. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 19.93 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $2.07. The business had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now owns 540,260 shares of the company’s stock, valued at $20,627,126.80. This represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Arturo Md Molina sold 30,514 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the transaction, the insider now directly owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,776 shares of company stock valued at $3,368,010. 5.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently commented on PTGX. Wedbush reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Tuesday, March 11th. JPMorgan Chase & Co. increased their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. The Goldman Sachs Group lowered their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, February 24th. Finally, Truist Financial boosted their price target on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a “buy” rating in a report on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $61.22.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.